Sera Prognostics Announces Board Transition and Key Corporate Updates
Key Points for Investors
- Board Change: Jeff Elliott will step down from Sera Prognostics’ Board of Directors, effective June 4, 2026, and will not stand for re-election at the upcoming Annual Meeting of Shareholders.
- Leadership Continuity: The company is in advanced discussions with highly qualified candidates to join the Board and expects to announce a new appointment in the near term.
- Company Focus: Sera Prognostics remains committed to its core mission of improving maternal and neonatal health through innovative pregnancy biomarker diagnostics, most notably its flagship PreTRM® Test.
- Market Overview: The company operates in a high-need, high-cost area of healthcare, with preterm birth representing a significant medical and economic burden in the U.S.
- Forward-Looking Risks: The announcement includes forward-looking statements regarding the company’s direction and warns of standard risks such as need for additional capital, market acceptance, regulatory changes, and reimbursement challenges.
Detailed Article
Salt Lake City, June 1, 2026 – Sera Prognostics, Inc. (“The Pregnancy Company®”, Nasdaq: SERA), a leader in precision pregnancy care diagnostics, announced a key transition on its Board of Directors. Jeff Elliott, who has served as a Director since March 2025, has informed the company of his intention to step down from the Board, effective June 4, 2026. Elliott has also communicated that he will not seek re-election at the upcoming Annual Meeting of Shareholders.
Leadership Transition
Elliott’s tenure coincided with a period of growth and development for Sera Prognostics. In his statement, Elliott expressed continued confidence in the company’s mission and long-term prospects but cited increasing demands on his time as the reason for his departure. He emphasized his belief in Sera’s future, stating: “While I continue to believe strongly in the future of Sera, I have made the decision to step down due to increasing demands on my time and my desire to ensure the Company receives the level of focus it deserves.”
CEO Zhenya Lindgardt thanked Elliott for his “thoughtful counsel, contributions, and support” during his tenure, stressing the positive impact Elliott had on the company’s strategic direction. Lindgardt also reassured investors that Sera Prognostics is in advanced discussions with prospective Board candidates and expects to announce a new appointment soon—a move that highlights the company’s commitment to strong corporate governance and leadership continuity.
Company Overview and Market Opportunity
Sera Prognostics specializes in the development and commercialization of innovative diagnostic tests targeting complications in pregnancy, with a particular focus on the early prediction of preterm birth risk. Its flagship product, the PreTRM® Test, is the only broadly validated, commercially available, blood-based biomarker test that delivers early, individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The test is ordered by medical professionals for use between weeks 18 and 20 of pregnancy, enabling targeted interventions for at-risk women.
The company’s work addresses a pressing and persistent healthcare challenge. Preterm birth, defined as any birth before 37 weeks’ gestation, is the leading cause of illness and death in newborns. According to the 2025 March of Dimes Report Card, the U.S. earned a D+ grade for preterm birth for the fourth consecutive year, marking the longest stretch of the lowest grade in the report’s history. Preterm birth is associated with lifelong risks and significant healthcare costs, with U.S. annual expenditures to manage these complications estimated at approximately \$25 billion as of 2016.
Risks and Forward-Looking Statements
The company’s press release contains forward-looking statements regarding Board changes, expectations for new appointments, and ongoing strategic directives. Sera Prognostics specifically notes that revenues from the PreTRM® Test currently represent substantially all of the company’s revenue. Investors should be aware of several risks outlined by the company, including: net losses and cash generation; the need for additional capital; market and scientific acceptance of the PreTRM® Test; reliance on a concentrated customer base; competition; regulatory changes; and reimbursement dynamics. Any developments in these areas could materially impact future performance and share value.
Contact Information
- Investor Contact: Jennifer Zibuda, Head of Investor Relations, [email protected], +1 (801) 396-8043
- Media Contact: Nicole Kaplan at Allison Worldwide, [email protected], +1 (847) 721-6033
Potential Share Price Impact
The departure of a Board member, especially one involved during a significant phase of company growth, can be a price-sensitive event. Investors may interpret this as a risk or as a sign of internal change; however, the company’s prompt efforts to secure a qualified replacement and its reaffirmed commitment to its strategy could help mitigate negative sentiment. Additionally, any announcement regarding the new Board appointment could further influence the share price, depending on the experience and reputation of the incoming member.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as detailed in the company’s most recent SEC filings. Investors should conduct their own research and consult with a professional financial advisor before making any investment decisions.
